Company intelligence / Profile preview

Autotelic Bio

Cheongju-si, Chungcheongbuk-do, South Koreaautotelic.co.kr ↗

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Autotelic Bio develops innovative anti-cancer therapeutics using antisense oligonucleotides and small molecules, leveraging proprietary informatics-driven platforms to target undruggable proteins in cancer and other diseases. Their pipeline includes assets at various clinical stages up to Phase 3 trials, including first-in-class fixed-dose combinations for metabolic diseases and novel ASO therapies targeting key cancer pathways.

Therapeutic areas: PulmonologyCardiovascularOncology
Modalities: Antisense oligonucleotide (ASO)Small moleculeFixed dose combination (as a formulation approach)
Industry: Biotech

Drug pipeline

5 assets

ATB-1013

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Autotelic Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Autotelic Bio.

Explore the full profile